Noninferiority trials are used to assess whether the effect of a new drug is not worse than an active comparator by more than a noninferiority margin. If the difference between the new drug and the active comparator does not exceed this prespecified margin, noninferiority can be concluded. This margin must be specified based on clinical and statistical reasoning; however, it is considered as one of the most challenging steps in the design of noninferiority trials. Regulators recommend that the margin should be defined based on the historical evidence of the active comparator (the latter is often the well-established standard treatment of the disease), which can be performed by different approaches. There are several factors and assumptions ...
OBJECTIVES To compare noninferiority margins defined in study protocols and trial registry record...
There is a knowledge gap in designing so-called “non-inferiority trials”, which aim to show whether ...
In a non‐inferiority trial to assess a new investigative treatment, there may need to be considerati...
Noninferiority trials are used to assess whether the effect of a new drug is not worse than an activ...
Non-inferiority trials are used to assess whether the effect of a new drug is not worse than an acti...
[[abstract]]In an active controlled noninferiority trial without a placebo arm, one of the major con...
Noninferiority trials, in which a new treatment is compared with a standard active treatment, are be...
To explore characteristics of clinical trials that influence the choice of the noninferiority margin...
Noninferiority (NI) trials in drug research are used for the purpose of demonstrating that a new tre...
Background There is no consensus on the preferred method for defining the non-inferiority margin in ...
When designing a noninferiority/equivalence trial, the sponsor intends to show efficacy by demonstra...
Clinical investigators are increasingly testing treatments that have the primary benefit of decrease...
Choosing a noninferiority margin is one of the main challenges when designing a noninferiority trial...
The increasing popularity of noninferiority trials reflects the ongoing efforts to replace existing ...
Active-control noninferiority trials test the hypothesis that one intervention is no worse than anot...
OBJECTIVES To compare noninferiority margins defined in study protocols and trial registry record...
There is a knowledge gap in designing so-called “non-inferiority trials”, which aim to show whether ...
In a non‐inferiority trial to assess a new investigative treatment, there may need to be considerati...
Noninferiority trials are used to assess whether the effect of a new drug is not worse than an activ...
Non-inferiority trials are used to assess whether the effect of a new drug is not worse than an acti...
[[abstract]]In an active controlled noninferiority trial without a placebo arm, one of the major con...
Noninferiority trials, in which a new treatment is compared with a standard active treatment, are be...
To explore characteristics of clinical trials that influence the choice of the noninferiority margin...
Noninferiority (NI) trials in drug research are used for the purpose of demonstrating that a new tre...
Background There is no consensus on the preferred method for defining the non-inferiority margin in ...
When designing a noninferiority/equivalence trial, the sponsor intends to show efficacy by demonstra...
Clinical investigators are increasingly testing treatments that have the primary benefit of decrease...
Choosing a noninferiority margin is one of the main challenges when designing a noninferiority trial...
The increasing popularity of noninferiority trials reflects the ongoing efforts to replace existing ...
Active-control noninferiority trials test the hypothesis that one intervention is no worse than anot...
OBJECTIVES To compare noninferiority margins defined in study protocols and trial registry record...
There is a knowledge gap in designing so-called “non-inferiority trials”, which aim to show whether ...
In a non‐inferiority trial to assess a new investigative treatment, there may need to be considerati...